FDA 483 - Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. - September 28, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Evonik Rexim Nanning Pharmaceutical Co., Ltd. was inspected by the FDA from September 25-28, 2018. The inspection revealed significant deficiencies related to the qualification and monitoring of cold temperature storage, including a lack of temperature mapping, inadequate review of temperature excursion data, and failure to communicate temperature alarms to the Quality department for deviation initiation. These issues indicate a lack of control over critical storage conditions for temperature-labile reagents.
- Inspection Date
- September 28, 2018
- Product Type
- Drugs
ID · 99fe7a38-3f93-434c-b05c-0dfa50adeef6